Published • loading... • Updated
Drug Farm to Present Ophthalmologic and CNS Findings from Phase 1b Study of First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at ARVO 2026
Summary by Carroll County Mirror-Democrat
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Drug Farm to Present Ophthalmologic and CNS Findings from Phase 1b Study of First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at ARVO 2026
Drug Farm today announced ophthalmologic and central nervous system (CNS) findings from its Phase 1b study of DF-003,
·Mount Carroll, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
